FDA Issues Complete Response Letter Rejecting Remoxy Approval

FDA Logo
FDA Logo
In June 2018, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee met and voted against (14-3) the approval of Remoxy upon data review.

Pain Therapeutics announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for Remoxy (oxycodone extended-release) capsules for the management of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative options are inadequate. 

Remoxy contains oxycodone, a full opioid agonist, and utilizes the Company’s ORADUR technology which is designed to deter abuse via non-oral routes. The FDA previously issued a CRL in 2016 stating that the NDA could not be approved in its present form and required additional studies to substantiate the claims regarding 3 routes of abuse: injection, inhalation, and snorting. Then in June 2018, the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee met and voted against (14-3) the approval of Remoxy upon data review. 

In today’s CRL, the FDA stated, “The data submitted in [the] NDA do not support the conclusion that the benefits of [Remoxy] Extended-Release Capsules outweigh the risks.” 

“This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction. We have an innovative drug with a social purpose, and a staggering amount of data that easily supports best-in-class abuse deterrence versus OxyContin,” stated Remi Barbier, President & CEO of Pain Therapeutics. 

Related Articles

The Company plans on focusing its resources on Alzheimer’s disease research with its lead drug candidate PTI-125 and a blood test that could potentially detect or confirm the disease even before symptoms appear (PTI-125DX). 

Follow @ClinicalPainAdv

For more information visit PainTrials.com.

This article originally appeared on MPR